BiotechTube

WVE-006

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alpha-1 Antitrypsin Deficiency

Conditions

Alpha-1 Antitrypsin Deficiency

Trial Timeline

Jul 19, 2024 → Sep 1, 2026

NCT ID
NCT06405633

About WVE-006

WVE-006 is a phase 1/2 stage product being developed by WaVe Life Sciences for Alpha-1 Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06405633. Target conditions include Alpha-1 Antitrypsin Deficiency.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT06405633Phase 1/2Recruiting
NCT06186492Phase 1Completed

Competing Products

13 competing products in Alpha-1 Antitrypsin Deficiency

See all competitors
ProductCompanyStageHype Score
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) PlaceboNovartisPhase 2
52
VX-668 + PlaceboVertex PharmaceuticalsPhase 1
32
VX-864Vertex PharmaceuticalsPhase 2
51
ALN-AAT02 + Placebo + ALN-AAT02Alnylam PharmaceuticalsPhase 1/2
38
ARC-AAT Injection + DiphenhydramineArrowhead PharmaceuticalsPhase 1
30
ARC-AAT InjectionArrowhead PharmaceuticalsPhase 2
49
Alpha-1 MPGrifolsPhase 3
74
Alpha-1 MPGrifolsPhase 3
74
WVE-006WaVe Life SciencesPhase 1
28
INBRX-101/rhAAT-FcInhibrx BiosciencesPhase 1
28
Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mgKamadaPhase 2
44
KRRO-110Korro BioPhase 1/2
33
Alvelestat (MPH966)Mereo BioPharmaPhase 2
44

Other Products from WaVe Life Sciences

WVE-210201 (suvodirsen) + PlaceboPhase 2/3
60
WVE-N531Phase 2
47
WVE-N531Phase 1/2
36
WVE-120102 + PlaceboPhase 1/2
36
SAD: 30mg WVE-003 + SAD: 60mg WVE-003 + SAD: 90mg WVE-003 + SAD: Pooled Placebo + MD: 30mg WVE-003 + MD: PlaceboPhase 1/2
36